What we are studying
BCG is the most effective therapy for treating bladder cancers. However up to 40% of the treated patients failed to respond to the therapy. As a result, the non-responders’ treatment by second line therapies can be delayed for months. This research project is an effort to develop a blood test for predicting responses of bladder patients to the BCG therapy before treatment.
Parking will be validated for study-related visits